Zoledronic Acid

Key Product Details

Product Description

Zoledronic Acid is a potent bisphophonate farnesyl diphosphate (FPP) synthase inhibitor (IC₅₀ = 20 nM). Inhibits osteoclast-mediated bone resorption. Also inhibits Ras signaling and tumor growth, and induces apoptosis in pancreatic cancer cells. Reverses epithelial-mesenchymal transition and inhibits breast cancer cell renewal via inactivation of NF-κB.

Product Specifications for Zoledronic Acid

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Zoledronic Acid

The following data is based on the product molecular weight 272.09.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.5 mM	7.35 mL	36.75 mL	73.51 mL
2.5 mM	1.47 mL	7.35 mL	14.70 mL
5 mM	0.74 mL	3.68 mL	7.35 mL
25 mM	0.15 mL	0.74 mL	1.47 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 4 publications citing the usage of this product.

• Tassone Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br.J.Cancer 2003 PMID: 12799645
• Dunford Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J.Pharmacol.Exp.Ther. 2001 PMID: 11160603
• Schech Zoledronic acid reverses the epithelial-mesenchymal transition and inhibits self-renewal of breast cancer cells through inactivation of NF-κB. Mol.Cancer Ther. 2013 PMID: 23619300

Product Documents for Zoledronic Acid